📰 Alkermes News
Page 36 - Alkermes News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alkermes. Real-time updates on events, politics, business and more.
May 22, 2023
Starting this summer, Colorado's Prescription Drug Affordability Board will choose up to 18 high-cost drugs for review.
May 21, 2023
StockNews.com assumed coverage on shares of Alkermes (NASDAQ:ALKS – Get Rating) in a report issued on Thursday. The firm issued a strong-buy rating on the stock. Several other research analysts have also recently commented on ALKS. HC Wainwright raised their target price on shares of Alkermes from $32.00 to $34.00 in a report on Thursday, […]
May 21, 2023
Vise Technologies Inc. lifted its position in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 96.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,149 shares of the company’s stock after acquiring an additional 10,395 shares during the period. […]
May 17, 2023
Operator: Welcome to Acorda Therapeutics First Quarter 2023 Financial and Business Update. [Operator Instructions]. Please be advised that this call is being recorded at the companys request.
May 16, 2023
? Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder ? DUBLIN, May 16, 2023 /PRNewswire/ -- Alkermes
May 14, 2023
Alkermes plc (NASDAQ:ALKS – Get Rating) saw a large drop in short interest during the month of April. As of April 30th, there was short interest totalling 7,600,000 shares, a drop of 13.9% from the April 15th total of 8,830,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is currently […]
May 12, 2023
Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of...
May 12, 2023
The Business Research Companys Substance Abuse And Addiction Treatment Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032
May 11, 2023
/PRNewswire/ -- The "Global Central Nervous System Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.coms...
May 9, 2023
The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In